Morgan Stanley analyst Maxwell Skor downgraded TScan Therapeutics (TCRX) to Equal Weight from Overweight. The firm’s new base case price target is now $1-$5 vs. $7-$13 prior. After the company’s recent strategic prioritization update, the firm plans to remain on the sidelines until there is greater visibility on near-term catalysts, the analyst tells investors in a research note. This change reflects that the pivotal TSC-101 study is now expected to initiate in Q2 of FY26 vs. prior forecast of the second half of FY25, the firm added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TCRX:
- TScan Therapeutics Reports Increased Revenue Amid Rising Losses
- TScan Therapeutics: Strategic Focus and Financial Stability Drive Buy Rating
- Promising Phase I Results and Strategic Adjustments Support Buy Rating for TScan Therapeutics
- TScan Therapeutics reports Q3 EPS (28c), consensus (33c)
- TScan Therapeutics downgraded to Neutral from Buy at BTIG